Department of Psychiatry and Psychology
Department of Pharmacology
Jacksonville, Jacksonville, Florida 32224
1. Akaike A, Sasa M, Takaori S. Muscarinic inhibition as a dominant role in cholinergic regulation of transmission in the caudate nucleus. J Pharmacol Exp Ther 1988;246:1129–1136.
2. Amano T, Richelson E, Nirenberg M. Neurotransmitter synthesis by neuroblastoma clones. Proc Natl Acad Sci USA 1972;69:258–263.
3. Ashkenazi A, Peralta EG, Winslow JW, Ramachandran J, Capon DJ. Functionally distinct G proteins selectively couple different receptors to PI hydrolysis in the same cell. Cell 1989;56:487–493.
4. Avissar S, Murphy DL, Schreiber G: Magnesium reverses lithium inhibition of beta adrenergic and muscarinic receptor coupling to G-proteins. Biochem Pharmacol 1991;41:171–175.
5. Avissar S, Schreiber G, Danon A, Belmaker RH. Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature 1988;331:440–442.
6. Avissar S, Schreiber G. Muscarinic receptor subclassification and G-proteins: significance for lithium action in affective disorders and for the treatment of the extrapyramidal side effects of neuroleptics. Biol Psychiatry 1989;26:113–130.
7. Axelrod J, Burch RM, Jelsema CL. Receptor-mediated activation of phospholipase A2 via GTP-binding proteins: arachidonic acid and its metabolites as second messengers. Trends Neurosci 1988;11:117–123.
8. Berridge MJ, Irvine RF. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature 1984;312:315–321.
9. Berridge MJ, Downes CP, Hanley MR. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J 1982;206:587–595.
10. Berridge MJ. Rapid accumulation of inositol trisphosphate reveals that agonists hydrolyse polyphosphoinositides instead of phosphatidylinositol. Biochem J 1983;212:849–858.
11. Bersudsky Y, Vinnitsky I, Grisaru N, et al. The effect of inositol on lithium-induced polyuria-polydipsia in rats and humans. Hum Psychopharmacol Clin Exp 1992;7:403–407.
12. Birdsall N, Buckley N, Doods H, et al. Nomenclature for muscarinic receptor subtypes recommended by symposium. Trends Pharmacol Sci 1989;Dec(Suppl):VII.
13. Blair LAC, Levitan ES, Marshall J, Dionne VE, Barnard E. Single subunits of GABAA receptor form ion channels with properties of the native receptor. Science 1988;242:577–579.
14. Bolden C, Cusack B, Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 1992;260:576–580.
15. Bonner TI, Young AC, Brann MR, Buckley NJ. Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1988;1:403–410.
16. Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic acetylcholine receptor genes. Science 1987;237:527–532.
17. Brooks RC, McCarthy KD, Lapetina EG, Morell P. Receptor-stimulated phospholipase A2 activation is coupled to influx of external calcium and not to mobilization of intracellular calcium in C62B glioma cells. J Biol Chem 1989;264:20147–20153.
18. Buckley NJ, Bonner TI, Brann MR. Localization of a family of muscarinic receptor mRNAs in rat brain. J Neurosci 1988;8:4646–4652.
19. Chalifour RJ, Kanfer JN. Microsomal phospholipase D of rat brain and lung tissues. Biochem Biophys Res Commun 1980;96:742–747.
20. Conklin BR, Brann MR, Buckley NJ, Ma AL, Bonner TI, Axelrod J. Stimulation of arachidonic acid release and inhibition of mitogenesis by cloned genes for muscarinic receptor subtypes stably expressed in A9 L cells. Proc Natl Acad Sci USA 1988;85:8698–8702.
21. Conti-Tronconi BM, Hunkapiller MW, Lindstrom JM, Raftery A. Subunit structure of the acetylcholine receptor from electrophorus electricus. Proc Natl Acad Sci USA 1982;79:6489–6493.
22. Dale HH. The action of certain esters and ethers of choline, and their relation to muscarine. J Pharmacol Exp Ther 1914;6:147–190.
23. Danoff SK, Ferris CD, Donath C, et al. Inositol 1,4,5-trisphosphate receptors: distinct neuronal and nonneuronal forms derived by alternative splicing differ in phosphorylation. Proc Natl Acad Sci 1991;88:2951–2955.
24. Davis KL, Hollister LE, Berger PA, Barchas JD. Cholinergic imbalance hypotheses of psychoses and movement disorders: strategies for evaluation. Psychopharmacol Commun 1975;1:533–543.
25. Dell'Acqua ML, Carroll RC, Peralta EG. Transfected m2 muscarinic acetylcholine receptors couple to Gai2 and Gai3 in Chinese hamster ovary cells—activation and desensitization of the phospholipase-C signaling pathway. J Biol Chem 1993;268:5676–5685.
26. Diaz-Meco MT, Larrodera P, Lopez-Barahona M, Cornet ME, Barreno PG, Moscat J. Phospholipase C-mediated hydrolysis of phosphatidylcholine is activated by muscarinic agonists. Biochem J 1989;263:115–120.
27. Dorje F, Wess J, Lambrecht G, Tacke R, Mutschler E, Brann MR. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther 1990;256:727–733.
28. Drachman DA, Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974;30:113–121.
29. Eberlein VW, Schmidt G, Reuter A, Kutter E. Anti-ulcer agent pirenzepine (L-S 519)—a tricyclic compound with particular physico-chemical properties. Arzneimittelforschung/Drug Res 1977; 27:356–359.
30. Ehrlich P. Veber den jetzigen Stand der Chemotherapie. Ber Dtsch Chem Ges 1909;42:17–47.
31. Exton JH. Signaling through phosphatidylcholine breakdown. J Biol Chem 1990;265:1–4.
32. Felder CC, Dieter P, Kinsella J, et al. A transfected m5 muscarinic acetylcholine receptor stimulates phospholipase A2 by inducing both calcium influx and activation of protein kinase C. J Pharmacol Exp Ther 1990;255:1140–1147.
33. Fisher SK, Agranoff BW. Receptor activation and inositol lipid hydrolysis in neural tissues. J Neurochem 1987;48:999–1017.
34. Fukami Y, Nishizuka Y. The protein kinase c family in signal transduction and cellular regulation. In: Papa S, Azzi A, Tager J, eds. Adenine nucleotides in cellular energy transfer and signal transduction. Basel: Birkhäser Verlag, 1992;201–205.
35. George WJ, Polson JB, O'Toole AG, Goldberg ND. Elevation of guanosine 3¢,5¢-cyclic phosphate in rat heart after perfusion with acetylcholine. Proc Natl Acad Sci USA 1970;66:398–403.
36. Gilman AG. G proteins: transducers of receptor-generated signals. Annu Rev Biochem 1987;56:615–649.
37. Goldberg N:R, Haddox MT. Cyclic GMP. Adv Cyclic Nucleotide Res 1973;3:155–223.
38. Goyal RK, Rattan S. Neurohumoral, hormonal and drug receptors for the lower esophageal sphincter. Gastroenterol 1978;74:598–619.
39. Gustavsson L, Hansson E. Stimulation of phospholipase D activity by phorbol esters in cultured astrocytes. J Neurochem 1990;54:737–742.
40. Hallcher LM, Sherman WR. The effects of lithium ion and other agents on the activity of myoinositol-1-phosphatase from bovine brain. J Biol Chem 1980;255:10896–10901.
41. Hammer R, Berrie CP, Birdsall NJM, Burgen ASV, Hulme EC. Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 1980;283:90–92.
42. Herrera R, Rosen OM. Regulation of the protein kinase activity of the human insulin receptor. J Recept Res 1987;7:405–415.
43. Hokin MR, Hokin LE. Enzyme secretion and the incorporation of P32 into phospholipides of pancrease slices. J Biol Chem 1953;203:967–977.
44. Houslay MD. Review: G-protein linked receptors—a family probed by molecular cloning and mutagenesis procedures. Clin Endocrinol 1992;36:525–534.
45. Hughes AR, Harden TK. Adenosine and muscarinic cholinergic receptors attenuate cyclic AMP accumulation by different mechanisms in 1321N1 astrocytoma cells. J Pharmacol Exp Ther 1986;237:173–178.
46. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ. Parasympathetic suppression of manic symptoms by physostigmine. Arch Gen Psychiatry 1973;28:542–545.
47. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ. A cholinergic–adrenergic hypothesis of mania and depression. Lancet 1972;1:632–635.
48. Jones SVP. Muscarinic receptor subtypes—modulation of ion channels. Life Sci 1993;52:457–464.
49. Kanba S, Kanba KS, Richelson E. The protein kinase C activator, 12-O-tetradecanoylphorbol-13-acetate (TPA), inhibits muscarinic (M1) receptor-mediated inositol phosphate release and cyclic GMP formation in murine neuroblastoma clone (N1E-115). Eur J Pharmacol 1986;125:155–156.
50. Karson CN, Garcia-Rill E, Biedermann J, et al. The brain stem reticular formation in schizophrenia. Psychiatry Res Neuroimaging 1991;40:31–48.
51. Kenakin TP. The classification of drugs and drug receptors in isolated tissues. Pharmacol Rev 1984;36:165–222.
52. Kendall DA. Cyclic GMP formation and inositol phosphate accumulation do not share common origins in rat brain slices. J Neurochem 1986;47:1483–1489.
53. Kim D, Lewis DL, Graziadai L, Neer EJ, Gar-Sagi D, Clapham DE. G-protein bg-subunits activate the cardiac muscarinic K+-channel via phospholipase A2. Nature 1989;337:557–560.
54. Kubo T, Maeda A, Sugimoto K, et al. Primary structure of porcine cardiac muscarinic acetylcholine receptor deduced from the cDNA sequence. FEBS Lett 1986;209:367–372.
55. Kubo T, Fukuda K, Mikami A, et al. Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature 1986;323:411–416.
56. Langley JN. On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curare. J Physiol (Lond) 1905;374–413.
57. Liao CF, Themmen APN, Joho R, Barberis C, Birnbaumer M, Birnbaumer L. Molecular cloning and expression of a fifth muscarinic acetylcholine receptor. J Biol Chem 1989;264:7328–7337.
58. Manji HK. G-proteins—implications for psychiatry. Am J Psychiatry 1992;149:746–760.
59. Matsuzawa H, Nirenberg M. Receptor-mediated shifts in cGMP and cAMP levels in neuroblastoma cells. Proc Natl Acad Sci USA 1975;72:3472–3476.
60. Mckinney M, Bolden C, Smith C, Johnson A, Richelson E. Selective blockade of receptor-mediated cyclic GMP formation in N1E-115 neuroblastoma cells by an inhibitor of nitric oxide synthesis. Eur J Pharmacol 1990;178:139–140.
61. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide—physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109–142.
62. Peralta EG, Ashkenazi A, Winslow JW, Smith DH, et al. Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J 1987;6:3923–3929.
63. Peralta EG, Winslow JW, Peterson GL, et al. Primary structure and biochemical properties of an M2 muscarinic receptor. Science 1987;236:600–605.
64. Peralta EG, Ashkenazi A, Winslow JW, Ramachandran J, Capon DJ. Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature 1988;334:434–437.
65. Popot JL, Sugiyame H, Changeux JP. Studies on the electrogenic action of acetylcholine with torpedo marmorata electric organ II. The permeability response of the receptor-rich membrane fragments to cholinergic agonists in vitro. J Mol Biol 1976;106:469–483.
66. Qian Z, Drewes LR. Muscarinic acetylcholine receptor regulates phosphatidylcholine phospholipase D in canine brain. J Biol Chem 1989;264:21720–21724.
67. Raiteri M, Marchi M, Paudice P, Pittaluga A. Muscarinic receptors mediating inhibition of g-aminobutyric acid release in rat corpus striatum and their pharmacological characterization. J Pharmacol Exp Ther 1990;254:496–501.
68. Raiteri M, Leardi R, Marchi M. Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain. J Pharmacol Exp Ther 1984;228:209–214.
69. Richelson E, Kanba S, Kanba KS, Pfenning M. Phosphoinositides and cyclic GMP in neural cells. In: Tucek S, ed. Synaptic transmitters and receptors. Chichester: John Wiley & Sons, 1987;315–318.
70. Rodbell M, Birnbaumer L, Pohl SL, Krans MJ. The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. V. An obligatory role of guanyl nucleotides in glucagon action. J Biol Chem 1971;246:1877–1882.
71. Safer DJ, Allen RP. The central effects of scopolamine in man. Biol Psychiatry 1971;3:347–355.
72. Sandmann J, Peralta EG, Wurtman RJ. Coupling of transfected muscarinic acetylcholine receptor subtypes to phospholipase-D. J Biol Chem 1991;266:6031–6034.
73. Sandmann J, Peralta EG, Wurtman RJ. Coupling of transfected muscarinic acetylcholine receptor subtypes to phospholipase-D. J Biol Chem 1991;266:6031–6034.
74. Sandmann J, Wurtman RJ. Phospholipase D and phospholipase C in human cholinergic neuroblastoma (LA-N-2) cells: modulation by muscarinic agonists and protein kinase C. In: Nishizuka Y, Endo M, Tanaka C, eds. The biology and medicine of signal transduction. New York: Raven Press, 1990;176–181.
75. Schofield PR, Darlison MG, Fujita N, et al. Sequence and functional expression of the GABA receptor shows a ligand-gated receptor super-family. Nature 1987;328:221–227.
76. Schreiber G, Avissar S, Danon A, Belmaker RH: Hyperfunctional G proteins in mononuclear leukocytes of patients with mania. Biol Psychiatry 1991;29:273–280.
77. Schultz G, Hardman JG, Schultz K, Baird CE, Sutherland W. The importance of calcium ions for the regulation of guanosine 3¢,5¢-monophosphate levels. Proc Natl Acad Sci USA 1973;70:3889–3893.
78. Singh S, Lowe DG, Thorpe DS, Rodriguez H, et al. Membrane guanylate cyclase is a cell-surface receptor with homology to protein kinases. Nature 1988;334:708–712.
79. Sitaram N, Nurnberger JI, Gershon ES, Gillin JC. Faster cholinergic REM sleep induction in euthymic patients with primary affective illness. Science 1980;208:200–202.
80. Snider RM, McKinney M, Forray C, Richelson E. Neurotransmitter receptors mediate cyclic GMP formation by involvement of phospholipase A2 and arachidonic acid metabolites. Proc Natl Acad Sci USA 1984;81:3905–3909.
81. Spiegel AM, Shenker A, Weinstein LS. Receptor–effector coupling by g-proteins—implications for normal and abnormal signal transduction. Endocr Rev 1992;13:536–565.
82. Stanton TT, Bolden-Watson C, Cusack B, Richelson E. Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. Biochem Pharmacol 1993;45:2352–2354.
83. Strosznajder J, Samochocki M. Ca2+-independent, Ca2+-dependent, and carbachol-mediated arachidonic acid release from rat brain cortex membrane. J Neurochem 1991;57:1198–1206.
84. Sutherland E. Studies on the mechanism of hormone action. Science 1972;177:401–408.
85. Tandon R, Dequardo JR, Goodson J, Mann NA, Greden JF. Effect of anticholinergics on positive and negative symptoms in schizophrenia. Psychopharmacol Bull 1992;28:297–302.
86. Tandon R, Shipley JE, Greden JF, Mann NA, Eisner WH, Goodson J. Muscarinic cholinergic hyperactivity in schizophrenia—relationship to positive and negative symptoms. Schizophrenia Res 1991;4:23–30.
87. Tang WJ, Gilman AG. Type-specific regulation of adenylyl cyclase by G-protein bg-subunits. Science 1991;254:1500–1503.
88. Tonnaer JADM, Cheung CL, De Boer T. cGMP formation and phosphoinositide turnover in rat brain slices are mediated by pharmacologically distinct muscarinic acetylcholine receptors. Eur J Pharmacol Mol Pharmacol Sect 1991;207:183–188.
89. Vilaro MT, Palacios JM, Mengod G. Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry. Neurosci Lett 1990;114:154–159.
90. Vizi ES, Kobayashi O, Torocsik A, et al. Heterogeneity of presynaptic muscarinic receptors involved in modulation of transmitter release. Neuroscience 1989;31:259–267.
91. Waelbroeck M, Tastenoy M, Camus J, Christophe J. Binding of selective antagonists to four muscarinic receptors (M1 to M4) in rat forebrain. Mol Pharmacol 1990;38:267–273.
92. Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 1993;259:528–531.
93. Waldman SA, Murad F. Cyclic GMP synthesis and function. Pharmacol Rev 1987;39:163–196.
94. Wallace MA, Claro E. A novel role for dopamine: inhibition of muscarinic cholinergic-stimulated phosphoinositide hydrolysis in rat brain cortical membranes. Neurosci Lett 1990;110:155–161.
95. Wamsley JK, Zarbin MA, Kuhar MJ. Distribution of muscarinic cholinergic high and low affinity agonist binding sites: a light microscopic autoradiographic study. Brain Res Bull 1984;12:233–243.
96. Wang S-Z, El-Fakahany EE. Application of transfected cell lines in studies of functional receptor subtype selectivity of muscarinic agonists. J Pharmacol Exp Ther 1993;266(1):237–243.
97. Warpman U, Alafuzoff I, Nordberg A. Coupling of muscarinic receptors to GTP proteins in postmortem human brain—alterations in Alzheimer's disease. Neurosci Lett 1993;150:39–43.